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ΠΕΡΙΛΗΨΗ  
Η ελονοσία αναγνωρίζεται ως μια από τις πιο ολέθριες απειλές υγείας παγκοσμίως, 
αφαιρώντας τη ζωή σχεδόν ενός εκατομμυρίου ανθρώπων ετησίωςς, κυρίως παιδιών 
ηλικίας κάτω των πέντε ετών. Η μετάδοση πραγματοποιείται μέσω του κουνουπιού-φορέα 
Anopheline. Τα γαμετοκύτταρα είναι οι μοναδικές μορφές του πλασμωδίου που μπορούν 
να αναπτυχθούν περαιτέρω μέσα στο στομάχι του κουνουπιού. Εφ’ όσον τα βιώσιμα 
γαμετοκύτταρα είναι απαραίτητα για τη μετάδοση της ασθένειας, η παραγωγή τους 
αποτελεί στόχο για την παρεμπόδιση της μετάδοσης. Σε αυτή την εργασία μελετήσαμε 
παράσιτα Plasmodium berghei, που προκαλούν ελονοσία σε τρωκτικά και 
χρησιμοποιούνται ως μοντέλα, τα οποία δεν περιέχουν το γονίδιο ανθεκτικότητας σε 
φάρμακα mrp1. Τα αποτελέσματά μας δείχνουν ότι η έλλειψη της MRP1 πρωτεΐνης οδηγεί 
σε μείωση της παραγωγής γαμετοκυττάρων στο P. berghei. Η μεταβολομική ανάλυση 
έδειξε μεγάλη ομοιότητα μεταξύ των μεταβολικών προφίλ παρασίτων αγρίου τύπου και 
των MRP1 μεταλλαγμένων, καθ’ όλο τον κύκλο ζωής στα ασεξουαλικά στάδια. 
Διαφοροποίηση παρατηρήθηκε σε ελάχιστους μεταβολίτες, ένας εκ των οποίων ήταν το γ-
αμινοβουτυρικό οξύ (GABA), το οποίο βρέθηκε σε χαμηλότερη συγκέντρωση στα MRP1 
μεταλλαγμένα παράσιτα συγκριτικά με τα αγρίου τύπου. Στη συνέχεια, προχωρήσαμε στη 
διευκρίνιση του ρόλου του GABA στα σεξουαλικά στάδια διαγράφοντας ορισμένα γονίδια 
που πιθανόν εμπλέκονται στο μεταβολισμό του GABA στο P. berghei. Καταφέραμε να 
απομακρύνουμε πέντε από τα έξι γονίδια που στοχεύσαμε. Η φαινοτυπική ανάλυση που 
έχει πραγματοποιηθεί στις μεταλλαγμένες σειρές παρασίτων ως τώρα, υποδεικνύει ότι η 
διατάραξη του μεταβολισμού του GABA επηρεάζει την παραγωγή μαστιγίων και την 
ανάπτυξη των ωοκινών, τα οποία αποτελούν τα κύρια στάδια ανάπτυξης του παρασίτου 
στο κουνούπι-φορέα.   
ABSTRACT 
Malaria is recognized as one of the most devastating worldwide health threats that 
claims the lives of almost a million people yearly, mainly of children under five years of age. 
Transmission occurs though Anopheline mosquito vectors. Gametocytes are the only forms 
of the malaria parasite that can undergo further development inside the mosquito midgut. 
Since viable gametocytes are crucial for transmission of the disease, production of 
gametocytes is a target for transmission blocking. In this project we studied Plasmodium 
berghei parasites, a rodent malaria model, lacking the multi-drug resistant protein (MRP1) 
gene. Our results show that lack of the MRP1 protein resulted in reduction of gametocyte 
production in P. berghei. Metabolomics analyses showed high similarity between the 
metabolic profiles of the wild type and the MRP1 mutant parasites in general across the life 
cycle in asexual stages except for a few metabolites, one of which was γ-Amino Butyric Acid 
(GABA) which was found to be in lower abundance in MRP1 mutant parasites compared to 
wild type. We proceeded to elucidate the role of GABA in the sexual stages with deletion of 
certain genes that are possibly involved in GABA metabolism in P. berghei. We were able to 
knock out five genes out of six that we attempted and the phenotypic analysis performed on 
these mutants so far, suggests that disruption of GABA metabolism seems to affect 
exflagellation and ookinete development which are key events in the mosquito stage 
development of the malaria parasite. 
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1 INTRODUCTION 
1.1 General information about malaria 
According to the WHO in 2012 approximately 3.4 billion people were living at the 
risk of contracting malaria. More than a third of these people (1.2 billion) were mostly 
residents in the African and South East Asian Region. In spite of the worldwide efforts to 
control and efficiently treat malaria, 207 million cases of malaria were reported in 2012, of 
which approximately 627,000 resulted in death. Almost 90% of the reported deaths each 
year occur in sub-Saharan Africa and about 77% in children under the age of 5. Although 
half the world’s population is living at the risk of the disease, there has been a worldwide 
decrease both in malaria cases and mortality rates. However, the 2013 World Health 
Organisation report states that malaria is still endemic in 104 countries and territories 1 
(Figure 1) and there is a rising threat to current treatment strategies due to increasing drug 
resistance.  
 
Figure  1:  Map showing distribution of malaria around the world. 
Regions affected by malaria are marked red. 
Wellcome Trust Sanger Institute, 2008 
 
Plasmodium species 
Malaria is caused by intraerythrocytic protozoa of the genus Plasmodium and is 
transmitted by the bite of an infected female mosquito of the genus Anopheles. Five 
species are responsible for malaria in humans; P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi. Of the five species, most dangerous and widely spread are P. falciparum 
and P. vivax1. 85% of all malaria cases and nearly all deaths are caused by P. falciparum, 
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making it the most deadly of the five species. It is possible that P. falciparum originated 
from P. reichenowi, a chimpanzee malaria parasite2. 
Plasmodium vivax was considered to be less lethal than P. falciparum because it 
rarely resulted in death. Nevertheless, vivax malaria is also a life threatening disease, as P. 
vivax possesses some features that, unlike P. falciparum, enable the parasites to survive 
during winter months and spread to more regions. P. vivax can develop in the Anopheles 
vector in lower temperatures than P. falciparum and the parasites can remain in a 
dormant, hypnozoite stage for long periods of time3. 
 
 
Treatment of malaria 
Vaccines  
An efficient vaccine against malaria would prevent the development of the sexual 
stages of the parasite and therefore block transmission and simultaneously stop spread and 
replication of asexual blood parasites which are responsible for the pathology of the 
disease4. The most studied types of vaccine candidates are: 
1) Transmission blocking vaccines with intention to block the development of the 
sexual stages of the parasite in the mosquito midgut or salivary glands. 
2) Pre-erythrocytic vaccines, aiming to kill the parasites at the liver stage and prevent 
their release into the bloodstream of the human host. 
3) Blood stage vaccines which are targeted against membrane antigens of the 
parasite in order to block the invasion of erythrocytes by parasites5. 
Drugs - resistance 
Development of new efficient antimalarial drugs has been a struggle because the 
parasites easily acquire resistance to effective drugs rendering them unsuitable for wide 
use. Drugs such as chloroquine and sulfadoxine-pyrimethamine used to be the first 
powerful drugs against the disease and helped eliminate malaria from North America, 
Europe and parts of Asia and South America before the parasites acquired resistance to 
the drugs. Some of the new drugs used to treat malaria are artemisinin and its derivatives, 
atovaquone, proguanil and chloroquine; chloroquine is mostly used for P. vivax infections 
as P. falciparum resistant lines have been reported6. The first cases of chloroquine resistant 
parasites were reported in the late 1940s and within a short period of time the resistance 
spread to most areas where malaria is considered endemic. P. falciparum has acquired 
resistance to almost all the antimalarial drugs that have been used to date. Although 
artemisinin and its derivatives have proven to be powerful drugs, the recent indications of 
acquisition of artemisinin resistance makes the need for new effective drugs imperative7. 
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Malaria control efforts 
Since 2010 malaria control programmes have been able to expand their control 
policies due to increased financing. As a result, there has been a worldwide reduction of 
malaria incidents and deaths with a 45% drop in mortality rates noted in all ages in the 
period of 2000-2012 (Figure 2). In 2013 the funding that was internationally disposed for 
malaria control efforts was 1.97 billion dollars1. Although this amount is not sufficient to 
reach the global targets set by the WHO it is a remarkable improvement over the 100 
million dollar funding of 2010. 
 
 
The strategies implemented in order to control and eliminate malaria include vector 
control, diagnostic testing and appropriate drug treatment.  
Vector control: the policies that are being applied in order to reduce the population of 
mosquitos as well as the human – vector interaction are: 
 Insecticide Treated mosquito Nets (ITN): World Health Organisation suggested the 
free distribution of ITNs to malaria endemic regions. Even though the number of 
ITNs delivered and used by people at risk is increasing, 100% ITN coverage has not 
been reached yet. 
 Indoor Residual Spraying (IRS): efforts for IRS have been restricted because of the 
confirmed resistance of mosquitos to at least one insecticide. In order to manage the 
threat of insecticide resistance, more costly non-pyrethoid insecticides are in use thus 
limiting the number of people that can be protected. 
 Intermittent Preventive Treatment (IPT): according to recent evaluations, IPT 
benefits 35 million pregnant women and a significant amount of the 26 million 
infants born, each year. 
Figure 2: Mortality rates 2000-2012. 
WHO report 2013 
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Diagnostic testing: diagnostic testing must be applied in public and private sectors in order 
to reduce the mistaken use of antimalarial drugs in suspected cases of malaria and increase 
the number of properly treated people with confirmed infections1. 
 
1.2 Plasmodium berghei 
P. berghei is one of the four Plasmodium species that infect murine rodents. 
Introduction of rodent parasites to the laboratory has contributed enormously to 
understanding the biology and immunology of malaria parasites. Rodent malaria parasites 
are commonly used for research purposes. Use of rodent malaria parasites has helped 
advance knowledge of the disease as well as the development of therapeutic measures. 
Despite some dissimilarity between rodent and mammalian malaria, rodent parasites have 
proven to be useful practical models since their structure, physiology and life cycle resemble 
those of mammalian parasites. 
Plasmodium berghei is an excellent research model for a number of reasons. Firstly, it is 
easily studied in vivo since it is not infectious to humans. Secondly, the basic biology, 
genetics and genome organisation remain similar between human and rodent malaria. 
The sexual stages of P. berghei can be cultivated in vitro and the purification of the 
parasite at various stages of the life cycle is possible. The genomes of both the parasite and 
the mosquito are known and there are technologies available for their genetic 
modification. Finally, there are several constructed lines that have been genetically 
modified in order to be advantageous for laboratory use, such as mutant parasites 
expressing reporter genes (Green Fluorescent Protein and Luciferase)8. 
 
Life cycle of Plasmodium berghei 
An infection begins with the bite of an infected female Anopheles mosquito and the 
subsequent release of the sporozoites in the blood stream of the vertebrate host (rodent) 
which are carried by the peripheral circulation and home to the liver invading its cells. 
Within the following 47-52 hours, the sporozoites grow inside the hepatocyte, divide and 
mature into schizonts containing haploid merozoites. In some species, such as P. vivax, the 
parasites can remain inactive in the liver for extended periods in the form of hypnozoites. In 
P. berghei there is no evidence of the hypnozoite stage in the liver. The merozoites are 
released from mature liver schizonts, enter the circulation and invade red blood cells. P. 
berghei has a strong preference for reticulocytes (immature erythrocytes) but can also 
invade mature red blood cells. Within an erythrocyte the merozoite grows from a ring 
stage into a mature trophozoite. The parasite then enters the schizont stage during which 
the parasite divides forming 8-24 merozoites. After the egress from a lysed erythrocyte, the 
newly formed merozoites are released in the circulation and reinvade erythrocytes. The lysis 
of a significant amount of erythrocytes during the asexual development of malaria 
parasites is responsible for the clinical manifestations of the disease. Some of the merozoite-
infected blood cells do not continue the cycle of asexual multiplication, instead they 
develop into sexual precursors, called gametocytes (Figure 3). In each blood stage cycle, 5-
25% of the parasites are committed to sexual differentiation. It is not known when 
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commitment to sexual differentiation takes place in P. berghei parasites. Even though 
there is evidence of the influence of innate and environmental factors in the switching 
mechanisms, the molecular mechanisms that induce and regulate the switch from asexual 
multiplication to sexual differentiation have only recently started to unravel9. Gametocytes 
through sexual reproduction are responsible for the transmission of the disease. There are 
some differences in the development of P. berghei and P. falciparum gametocytes. In P. 
berghei, the merozoites of liver schizonts are able to differentiate directly into gametocytes 
after invasion of the erythrocyte10. The developmental time needed for P. berghei 
gametocytes is 26-30 hours which is quite short compared to the 8-11 days P. falciparum 
gametocytes require to develop. Also the morphology of the gametocytes of these two 
species is different, P. falciparum has banana-shaped gametocytes and P. berghei has 
round to oval shaped gametocytes. When a mosquito feeds on an infected vertebrate host, 
it ingests Plasmodium infected erythrocytes including gametocytes, the only cells capable of 
further development in the mosquito midgut. In the mosquito midgut, gametocytes 
activate and differentiate into gametes. Differentiation of the female gametocyte 
produces a single female gamete, the macrogamete. The male gametocyte differentiates 
into eight sperm-like motile microgametes. The maturation process of the 
microgametocyte is known as exflagellation. The differentiation of the gametocytes has 
been shown to be generated by three environmental factors: a temperature drop of at 
least 5°C in the infected red blood cells (temperature of the red blood cells inside the mouse 
is 37°C, whereas in the mosquito it is 21°C), a rise in pH from 7.3 to 7.8-8.0 and the presence 
of a gametocyte activating factors such as xanthurenic acid. After activation male and 
female gametes fuse to form diploid zygotes. Within 18-24 hours the spherical zygote 
develops into a banana-shaped, motile ookinete which traverses the wall of the mosquito 
midgut and develops into an oocyst on the basal lamina. Growth and division within each 
oocyst produces thousands of haploid sporozoites; 1500-8000 sporozoites can be contained 
in each oocyst. Upon sporozoite maturation, after 8-15 days, the oocyst bursts releasing 
sporozoites which then travel to and invade the mosquito salivary glands (it has been 
found that only a small percentage of the sporozoites, about 2%, reach the salivary 
glands). The sporozoites can survive in the salivary glands for weeks before being injected 
into a new host. The cycle of infection re-starts when the mosquito takes a blood meal, 
injecting the sporozoites from its salivary glands into the bloodstream of the vertebrate 
host8, 11. 
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Figure 3: Life cycle of Plasmodium. 
Nature reviews/ Microbiology 11,701–712 (2013) 
 
Sexual differentiation in Plasmodium berghei 
The developmental switch from asexual multiplication to sexual development is 
induced and regulated by molecular mechanisms. As a result, a cascade of gene expression, 
involving a number of sexual-stage specific genes and their protein products, is activated. 
There is evidence that in both P. falciparum and P. berghei, the switching mechanism is 
regulated by innate and environmental factors. In P. falciparum some of the 
environmental conditions that can affect gametocytogenesis are the presence of 
erythrocyte lysate, host immune sera and lymphocytes, the drug chloroquine and high 
number of asexual parasites12.  
There is also evidence of the association of sexual commitment with heterotrimeric 
G proteins and the specific signal transduction pathways that can be activated by these 
proteins. When a G-protein coupled receptor binds to a ligand, the α subunit is activated 
and can interact with several effector molecules, such as adenylate cyclase or 
phospholipase C. The effector molecules can subsequently activate different enzymes such 
as Protein Kinase A (PKA) and Protein Kinase C (PKC) and finally result in activation of 
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transcription factors and expression of specific genes required for gametocytogenesis 
(Figure 4). The involvement of G proteins in sexual differentiation was supported by data 
which showed that gametocytogenesis is stimulated by  the addition of cholera toxin to P. 
falciparum cultures. Cholera toxin is an activator of the Gas class of heterotrimeric G-
proteins. Furthermore, it was demonstrated in P. falciparum that expression of the Ga 
subunits was stage-specific, with highest levels of expression during asexual development 
and in mature gametocytes. Since expression of G-proteins is considered a marker of the 
cell’s sensitivity to environmental conditions, increased expression of G-proteins in the free 
merozoite could account for the parasite’s response to the environmental conditions 
through different metabolic processes; processes which can, amongst other factors, define 
the number of parasites that will differentiate into gametocytes13. 
 
Figure 4: G-protein based signalling. 
    Dopamine Receptor D4 Database (G-Protein Coupled Receptors) 
 
 
Gametocyte non-producer lines of P. berghei 
The capability to produce gametocytes can be lost during prolonged periods of 
multiplication in the vertebrate host or in in vitro cultures when passage of the parasite 
through the mosquito does not occur. This is due to the loss of selection pressure as the 
parasite can continue its growth without transmission by the invertebrate host. It has been 
shown that lack of only one gene, AP2G gene (PBANKA_143750), is sufficient for loss of 
gametocytogenesis9. Line G401cl1 is an AP2G knock out and does not produce any 
gametocytes. 
 
Gametocyte low-producer lines of P. berghei 
In our laboratory we have observed that the level of production of gametocytes 
can be affected by the deletion of certain genes from P. berghei’s genome. Parasite lines 
 
18 
 
1025cl1 and 1512cl1 are gene deletion mutants of the MRP1 gene (PBANKA_144380) and 
produce low number of gametocytes. 
 Line 1512cl1 is made in 820 background meaning that the female gametocytes 
produce RFP and the male gametocytes GFP. 
 Line 1025cl1 is made in 507 background resulting in the production of GFP from the 
parasites all through the cell cycle. 
 
1.3 ABC transporters 
ATP binding cassette transporters are amongst the largest evolutionary conserved 
protein families. ABC transporters bind and hydrolyse ATP molecules to provide energy for 
the transportation of their substrates. These transporters are responsible for the 
translocation of various substrates, ranging from ions to macromolecules14. ABC 
transporters are located on the membrane and are categorised as importers or exporters 
depending on their function. Importers are only found in prokaryotes and are responsible 
for nutrient uptake15. ABC exporters are present in both eukaryotes and prokaryotes and 
play a key role in cellular exportation of endobiotics and xenobiotics15, 16. 
Overexpression of certain ABC exporter proteins contributes to drug resistance in 
organisms ranging from human neoplastic cells to parasitic protozoa. Although these 
proteins have mostly been studied for their role in cancer multidrug resistance, some 
members of the ABC family use the energy acquired from ATP hydrolysis for cellular 
processes, such as DNA repair and mRNA translation17. 
 
Multi-drug Resistant Protein 1 transporter 
The ABC transporter family is divided into 7 subfamilies, named from ABCA to 
ABCG. MRP1 belongs to the ABCC subfamily.MRP1-related proteins have been identified in 
mammals and in a variety of non-mammalian organisms including yeast18, protozoa, 
nematodes19 and plants20.MRP1 was the first gene of the ABCC subfamily to be identified in 
humans. The gene was identified because its overexpression resulted in resistance against 
many chemotherapeutic agents in a human lung cancer cell line21. 
Structure: Usually MRP1 proteins consist oftwo Nucleotide Binding Domains (NBDs) 
and two Membrane Spanning Domains (MSDs). Mammalian MRP1 transporters have a 5-
domain structure constituted by two NBDs and threeMSDs (Figure 5)22. 
Substrates and Function: MRP1 is responsible for the transportation of a wide range 
of substrates. It is suggested that overexpression of MRP1 leads to development of 
multidrug resistant cells. In humans, the transporter is considered critical mostly due to its 
ability to efflux variousanticancer drugs, such as anthracyclines and methotrexate, as well 
as plenty of other types of drugs e.g. anti- HIV drugs23. 
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Conjugates of glutathione, glucuronides and sulphate can be transferred across the 
cellular membrane by MRP1. These conjugates are products of Phase II metabolism in cells 
and their efflux by MRP1 is part of the cell detoxification from endo and xenobiotics. The 
transporter also has a high affinity for the conjugated cysteinyl leukotriene C4 (LTC4) 
which is a mediator of inflammatory response24. Several drugs can be effluxed by MRP1 
both as unconjugated and conjugated (usually with glutathione) organic anions. It has 
been shown that even in circumstances where the drugs do not form a conjugate with 
glutathione, their transport requires the presence of GSH. It was therefore suggested that 
glutathione is co-transported with some unconjugated substrates of MRP125, 26. MRP1 also 
participates in the protection of the cell from oxidative stress since it can transfer 
glutathione and its oxidized form, GSSG. Maintenance of a low GSSG:GSH ratio is crucial 
for prevention of oxidative stress and normal cell activity27. Therefore, in every organism 
where it is present, MRP1 contributes to the removal of toxins and the protection from endo 
and xenobiotic-induced damage. 
 
 
 
 
 
Figure 5: Structure of MRP1 protein. Mammalian MRP1 proteins have 
 a 5 domain structure; non-mammalian MRP1 proteins lack the MSD0. 
 
1.4 Metabolomics 
 
Metabolomics is the scientific study of chemical processes involving metabolites which 
are low molecular weight molecules, mostly intermediates or products of biological 
pathways in any organism.  In global metabolomics studies, the metabolome, which consists 
of all the metabolites of an organism, is studied in detail. The genome, the transcriptome 
and the proteome are comparatively more stationary nodes of flow of information within 
an organism, whereas the metabolome is dynamic and changes much more rapidly as a 
result of environmental factors, as well as gene expression and protein function and 
regulation. The metabolome is closest to the phenotype than the other three ‘omes’ 
mentioned above. Changes in the metabolome are the ultimate answer of an organism to 
genetic alterations28. 
Metabolomics offers qualitative and quantitative information about metabolites 
thus helping to define metabolic changes associated with conditions of interest, such as 
drug exposure, parasite-host interactions and mutations. Metabolomics studies usually aim 
to generate a snapshot of the physiological state of a system and determine how an 
external or internal stimulus can alter the biology of the system studied.  
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A metabolic analysis can be either targeted, when the aim is to detect variations of a 
particular set(s) of metabolites, or untargeted, when all potential metabolites that can be 
detected are examined. In targeted approaches the techniques used are nuclear magnetic 
resonance (NMR) spectroscopy and chromatography can be used to achieve good 
resolution before detection by mass spectrometry (MS). In untargeted approaches, liquid 
chromatography coupled with mass spectrometry (LC/MS) has proven to be the most 
effective combination of techniques for the measurement of the highest possible number of 
metabolites in a sample29. 
 
1.5 Tricarboxylic acid cycle in Plasmodium spp 
Plasmodium species primarily use glucose as the main energy source and depend on 
glycolysis for ATP synthesis. The product of glycolysis in Plasmodium spp. is lactate, via 
lactate dehydrogenase, rather than pyruvate. Pyruvate dehydrogenase is the enzyme that 
catalyses the decarboxylation of pyruvate into acetyl-CoA inside the mitochondrion. Upon 
its formation, acetyl-CoA feeds into the TCA cycle. The localisation of pyruvate 
dehydrogenase in the apicoplast of Plasmodium spp. suggests the lack of a TCA cycle30. 
Despite the fact that Plasmodium parasites do not use oxidative phosphorylation for ATP 
generation, the presence of a single mitochondrion seems to be essential for their growth31. 
In addition, although the parasites rely on glycolysis for energy production, all the necessary 
genes for the tricarboxylic acid cycle are present in the genome of Plasmodium spp. It was 
suggested that the branched chain a-keto acid dehydrogenase (BCKDH) complex, which is 
located in the mitochondrion, is involved in the conversion of pyruvate to acetyl-CoA32. 
The results of flavoprotein deletion in Plasmodium support the hypothesis of a 
functioning TCA cycle. Flavoprotein (Fp) is one of the subunits of the mitochondrial 
complex II, which catalyses the oxidation of succinate to fumarate. Deletion of gene 
Pbsdha, coding for Fp, had no effect in the development of blood stage parasites or 
gametocytes in P. berghei; it did however affect the mosquito stages and resulted in a 
block in transmission33. Finally, recent metabolomics studies in P. falciparum carbon 
metabolism revealed that both asexual and sexual stage parasites utilize the TCA cycle. 
This targeted analysis also demonstrated that although in asexual stages, in TCA 
metabolism, glutamate utilization is higher than glucose utilization, the opposite is 
occurring in gametocytes, where the parasites seem to switch to TCA catabolism of 
pyruvate32. 
All the data above suggest that although the TCA cycle is not imperative for parasite 
growth inside the red blood cell (blood stages), its disruption causes developmental issues 
when the parasites leave the host cell (in mosquito stages) or even earlier, during 
gametocytogenesis. It is thought that the parasites either switch their energy source from 
glycolysis to oxidative phosphorylation because glucose is no longer abundant during the 
mosquito stages, or they use both metabolic pathways in order to accumulate certain 
molecules in anticipation of the energy requirements of the sexual stages. 
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1.6 Gamma-Aminobutyric acid (GABA) 
Gamma-Aminobutyric acid is an amino acid known since the 1960s as the main 
inhibitory neurotransmitter in the mammalian central nervous system. GABA is produced 
by nearly all prokaryotes and eukaryotes, from bacteria to humans. Although for years 
research was focused on its role as a neurotransmitter and its effect on the nervous system 
in vertebrates, it has been recently implied that GABA participates in the regulation of a 
wide range of developmental stages, from cell proliferation to circuit refinement34. 
GABA is formed by a metabolic pathway called the GABA shunt. The first step is 
the formation of glutamate (Glu). Glutamate, the precursor of GABA, can be a product of 
either glucose or glutamine metabolism. Transamination of a-ketoglutarate, which is an 
intermediate of the TCA metabolism of glucose, by GABA a-oxoglutarate transaminase 
(GABA-T) results in the formation of glutamate. Glutamate can also be synthesized via the 
glutamate/glutamine cycle by a phosphate-activated glutaminase. Following its 
production, glutamate is decarboxylated to form GABA by an enzyme called glutamate 
decarboxylase (GAB).GABA can be used as an energy source feeding into the TCA cycle. 
GABA-T metabolizes GABA to succinic semialdehyde (SSA). SSA is subsequently oxidized 
by succinic semialdehyde dehydrogenase (SSADH) into succinate which can enter the TCA 
cycle35 (Figure 7). 
Figure 6: Tricarboxylic acid cycle in 
Plasmodium. The TCA cycle is proposed to 
function in Plasmodium parasites with chain 
 a-keto acid dehydrogenase (BCKDH) complex 
instead of pyruvate dehydrogenase. 
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Figure 7: GABA shunt. 
Gamma-Aminobutyric acid in Plasmodium spp. 
According to recent findings the GABA shunt is functional in Toxoplasma gondii36. 
However, things differ in Plasmodium spp. because the genome does not encode for the 
enzyme succinate semialdehyde dehydrogenase (SSADH), which is required for the 
conversion of GABA to succinate. Despite the lack of such an enzyme, when labelled 
glucose and glutamine where used in the media for cultures of P. falciparum parasites high 
levels of labelled GABA were detected only in infected red blood cells, thus suggesting the 
presence of a partial GABA shunt. In P. falciparum gametocytes GABA and glutamate 
were strongly labelled from 13C-glucose, whereas in schizonts the labelling was mostly 
coming from13C-glutamine. This could mean that the TCA cycle operates in asexuals but 
primarily in gametocytes and that TCA cycle intermediates are used for synthesis of 
glutamate and GABA32. P. berghei’s gametocytes seem to be accumulating GABA and the 
highest level of GABA was observed during ookinete development (unpublished data). As 
it was previously stated, disruption of the TCA cycle leads to non-functional ookinetes 
which fail to form oocysts in P. berghei33, also perturbation of the TCA cycle in P. 
falciparum parasites resulted in loss of viability of gametocytes. It is still unknown whether 
these defects during the parasite’s sexual stages are in any way connected with variations 
in GABA levels. 
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Gamma-Aminobutyric acid in signalling pathways 
Research about GABA in invertebrates was focused for several years on its role as a 
metabolite. However, recently there have been suggestions that GABA can also act as a 
signalling molecule. It was demonstrated that GABA accumulates rapidly in response to 
biotic and abiotic stresses in plants37. Furthermore, modifications in GABA metabolism 
pathways, e.g. mutants lacking enzymes necessary for GABA production or enzymes 
responsible for its degradation, usually result in growth inhibition and developmental 
problems38. Supporting the existence of GABA-mediated signalling pathways were the 
alterations in gene expression due to GABA. In Arabidopsis thaliana plants grown in the 
presence of GABA 71 genes were down-regulated and 36 genes were up-regulated, as 
compared to plants grown under standard conditions39. Furthermore, disruption of succinic 
semialdehyde dehydrogenase (SSADH) in A. thaliana resulted in the aggregation of 
reactive oxygen intermediates (ROS) when the plants were exposed to environmental 
stresses40.It was also proposed that GABA can function as a signal in the plant-
Agrobacterium tumefaciens interaction, affecting the extent to which Agrobacterium can 
spread inside the plant41. 
AIMS AND OBJECTIVES  
In this project we aimed to determine the impact that lack of the MRP1 gene would 
have on Plasmodium berghei parasites. Firstly, we performed phenotypic analysis of the 
mrp1 knock out compared to wild type parasites that revealed differences in the number 
of gametocytes produced by the two lines. The mutant parasites produce 70-80% less 
gametocytes than wild type parasites. The gametocytes produced by the mutant line, 
though fewer in number, are capable of normal exflagellation and ookinete conversion. 
Further on, we used metabolomics to reveal the differences between wild type and the 
MRP1 knock out lines with differential gametocyte conversion rates. The metabolomics 
analysis revealed that a unique metabolite, GABA, was involved in the sexual stages and 
we began to elucidate the role of GABA in the sexual stages of P. berghei. We aimed to 
disrupt GABA metabolism by knocking out genes that are possibly involved in it. Deletion 
of five out of the six genes we targeted was successful and cloning of three knock out lines 
was possible within the limited time we had. Finally, we checked whether loss of these 
genes would have any effect on the production of gametocytes, so we performed 
phenotypic analysis on the cloned mutant lines we created. 
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2a MATERIALS 
 
2a.1 Molecular Biology 
Buffers, Solutions and Media 
5x TBE electrophoresis buffer: 
445mM Tris, 445mM Boric acid, 10mM EDTA and ddH2O 
LB agar:  
1% pepton, 0.5% yeast extract, 1% NaCl and 1.5% agar 
LB broth: 
1% pepton, 0.5% yeast extract, 1% NaCl 
Ampicillin: 
Stock: 100mg/ml 
Final concentration in LB broth/agar: 100μg/ml 
TNE buffer: 
10mM Tris pH 8.0, 5mM EDTA pH 8.0, 100mM NaCl and demineralized water 
 
2a.2 Plasmodium berghei methods 
Buffers, Solutions and Media 
Phosphate buffered saline (PBS): 
The 10x PBS contains: 0.01M KH2PO4, 1.37M NaCl and 0.027M KCl, pH 7.0 
Erythrocyte-lysis buffer: 
The components of the 10x solution are: 1.5M NH4Cl (80.23g/l), 0.1MKHCO3 (10.012g/l) and 
0.01M EDTA (3.725g/l) 
Giemsa solution and staining buffer: 
The stock Giemsa solution is diluted in staining buffer. 40ml of Giemsa dye (12%) contain 
5ml of stock Giemsa solution and 35ml of Giemsa staining buffer 
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For 500ml of staining buffer 0.25gr KH2PO4, 0.05gr Na2HPO4 .2H2O are added and the 
pH is adjusted to 7.2 with NaOH 
Complete culture medium: 
RPMI 1640 pH 7.3 containing 25% v/v AlbuMAX provided by Invitrogen 
RPMI 1640 with L-glutamine and 25mM HEPES is provided by Invitrogen 
Ookinete culture medium: 
RPMI 1640 pH 7.3containing 10% v/v foetal calf serum and 10-100 mM of xanthurenicacid 
Minimal medium: 
For 10L of 10x stock: 
1gr Ca(NO3)2 .4H2O, 4gr KCl, 488mg MgSO4(anhydrous), 53gr NaCl, 20gr NaHCO3, 8gr 
NaHPO4(anhydrous), 41mg Hypoxanthine, 20gr D-Glucose, 10mg Glutathione, 59,58gr 
HEPES, 50mg Phenol Red, 650mg L-Cystine.2HCl, 200mg L-Glutamic Acid, 3gr L-
Glutamine, 500mg L-Isoleucine, 150mg L-Methionine, 200mg L-Proline, 300mg L-
Tyrosine.2Na.2H2O and 2.5mg Ca-Pantothenate 
All components were mixed and Pen-Strep (1ml/l) was added before use. pH was adjusted 
to 7.3, the medium was sterilized using a 0.22u filter and AlbuMAX (5g/L) was added.  
Nycodenz: 
138g of Nycodenz powder (LucronBioproduct BV) is dissolved in 500ml of Buffered 
Medium containing 302.85mg Tris/HCl (5mmol/l), 111.85mg KCl (3mmol/l) and 56.15mg Ca 
Na EDTA (0.3mmol/l) 
A 55% Nycodenz-normal PBS solution is used for purification of schizonts from an asexual 
culture. 
Pyrimethamine: 
Stock solution: dissolved pyrimethamine in DMSO to a final concentration of 7mg/ml 
100 times dilution of the stock solution in added in the drinking water 
Sulfadiazine: 
Mice are treated with 25mg/l sulfadiazine in the drinking water 
Phenylhydrazine-HCl (phz): 
125mg phz (12.5mg/ml) are dissolved in 10ml 0.9% NaCl 
100μl of stock solution are injected to each mouse i.p. 
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Gas mix: 
5% O2, 5% CO2 and 90% N2 
5-fluorocytocine: 
Mice are treated with 1.5mg/ml 5-fc in drinking water 
 
2a.3 Flow cytometry 
Buffers, Solutions and Media 
Hoechst dye: 
Hoechst dye is provided by Invitrogen 
The solution used in FACS protocol consists of 10μM Hoechst made up in enriched PBS 
Enriched PBS: 
Normal PBS enriches with 20mM Hepes, 20mM Glucose, 4mM NaHCO3 and 0.1% BSA 
FACS buffer: 
PBS and 3-5mM of EDTA 
 
2a.4 Metabolomics methods 
Buffers, Solutions and Media 
Internal standards: 
1μM 5-fluoroudine, 1μM Cl-phenyl-cAMP, 1μM N-methyl glucamine, 1μM Canavanine, 1μM 
Piperazine 
Extraction solvent: 
Chloroform: methanol: water::1: 3: 1 with internal standards (all at 1μM concentration each) 
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2b METHODS 
2b.1 Molecular Biology 
Polymerase Chain Reaction (PCR) 
In a 1.5ml Eppendorf tube the following solutions were added: genomic DNA from 
Plasmodium berghei parasites of the strain HPTBB (template), PCR buffer (-MgCl2), 
MgCl2, dNTPs, forward primer, reverse primer, Taq Polymerase and ddH2O. 
 
Table 1: PCR reagents for a 50μl reaction. 
Reagent Volume (μl) Initial 
Concentration 
Final 
Concentration 
HP DNA 1 50ng/μl 50ng 
PCR Buffer 5 10x 1x 
MgCl2 2 50mM 2mM 
dNTPs 5 2.5μM 0.05μM 
Primer F 2 10pmol/μl 20pmol 
Primer R 2 10pmol/μl 20pmol 
Taq 0.4 5units/ μl 2units 
ddH2O 32.6 - - 
 
The PCR was performed with the following cycling protocol:  
1. Initial denaturation for 3 minutes at 94oC   
2. Denaturation at 94oC for 30 seconds 
3. Annealing at 55oC for 30 seconds 
4. Extension at 68oC for 2 minutes 
5. Final extension 68oC for 10 minutes 
The annealing temperature of 55oC worked for all primer pairs, except for primers 
GU2930+GU2971. The LDC upstream region was acquired with an annealing temperature 
of 60oC. 
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 Primer Sequence Number  Restriction 
Enzyme 
GDH1 upstream 
forward 
actAAGCTTCTATGTATATATTTTTCGACATTTAACTGC GU2943 HindIII 
GDH1 upstream reverse catCCGCGGCAATGTAACAAATTATATAAGTATTTATTTGTTTG
TAT 
GU2944 SacII 
GDH1 downstream 
forward 
tcaGGTACCCGAGGATGCTTCGTATGATCTTAGCCAC GU2945 KpnI 
GDH1 downstream 
reverse 
ctaCTCGAGCCGAGATGTTGTAGAGCATCATATGTATGAC GU2946 XhoI 
GDH3 upstream 
forward 
actAAGCTTGGTTATGCAATATACTGACAAATATGTATAGCC GU2951 HindIII 
GDH3 upstream 
reverse 
catCCGCGGTAAGGGCGGGGGAGTAATATATATGTAATGT GU2952 SacII 
GDH3 downstream 
forward 
tcaGGTACCGAGTGTGCATGTTTTACTACATGTTTTGTATTAC GU2953 KpnI 
GDH3 downstream 
reverse 
ctaCTCGAGGGGAAATCAATCACTTCCGTTATACTACAA GU2954 XhoI 
OAT upstream forward atcGGGCCCGCGTAAGGCATGTATACATGATGTTATGTA GU2955 ApaI 
OAT upstream reverse ctaCCGCGGAGTACAAATGCAGGACAGAACACATTGCAA GU2956 SacII 
OAT downstream 
forward 
tcaGGTACCTAGAGGCATGTTGATGTTTACTAGTATATGC GU2957 KpnI 
OAT downstream 
reverse 
ctaCTCGAGATATGTCGTTTGTGTTAAGAATGATATGTACTG GU2958 XhoI 
Putative transporter 
upstream forward 
atcGGGCCCCGGAACTTTTCGAGCTATTATCATTATTTAATG GU2959 ApaI 
Putative transporter 
upstream reverse 
ctaCCGCGGTTGTAGTTGTCTTTGCTTGGGTCTATATGT GU2960 SacII 
Putative transporter 
downstream forward 
tcaGGTACCGAGCCAGGTGTTTATGTGTGTATATAAATGAT GU2961 KpnI 
Putative transporter 
downstream reverse 
ctaCTCGAGATCAGAACTTATCTCATACATAAATCTGGTGG GU2962 XhoI 
LDC upstream forward attGGGCCCGCTTTGATAATGTGATTAGCCCAGTGTG 
 
GU2930 ApaI 
LDC upstream reverse ctaCCGCGGCAACAAAGTGATCGTAGTACCCATATATATAG 
 
GU2871 SacII 
 
 
Table 2: Primers used for PCR amplification of downstream and upstream regions 
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High-Fidelity Polymerase Chain Reaction 
Amplification of GDH2 upstream and downstream regions as well as LDC 
downstream region was performed using the KAPA HiFi PCR Kit, which contains a 
proofreading DNA polymerase, to avoid any mutations in the adjacent genes. The kit is 
provided by KAPA Biosystems. 
 
 
 Primer Sequence Number  Restriction 
Enzyme 
GDH2 upstream 
forward 
atcGGGCCCCCTGAAGCATATGCTGCACATGCAA GU3065 ApaI 
GDH2 upstream 
reverse 
ctaCCGCGGGCACTATTTCCACACTATTTGTTACTACATTC GU3066 SacII 
GDH2 downstream 
forward 
tcaGGTACCCAAATGGAACCGAACCCTCAATTATATTTCC GU2949 KpnI 
GDH2 downstream 
reverse 
ctaCTCGAGGAGAGCCAAACATGTCAAATATCACGAG GU3067 XhoI 
LDC downstream 
forward 
tcaGGTACCGAAATGGCTGAGGATAAACATTACGAAAC GU3069 KpnI 
LDC downstream 
reverse 
ctaCTCGAGGGGTATGTCGCTAATGATAAGCATTGT GU3070 XhoI 
  
 
 
Component Volume (μl) Initial Concentration Final Concentration 
HP genomic DNA 1 50 ng/μl 50 ng 
KAPA FidelityHiFi Buffer 10 5x 1x 
dNTP mix 1.5 10 mM 0.3 mM each 
Primer F 1.5 10 μM 0.3 μM 
Primer R 1.5 10 μM 0.3 μM 
HiFi DNA Polymerase 1 1 U/μl 1 U 
ddH2O 33.3 - - 
 
 
 
Table 3: Primers used for Hi Fidelity PCR amplification of downstream and upstream regions 
Table 4: HiFi PCR reagents for a 50μl. 
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The PCR was performed with the following cycling protocol:  
6. Initial denaturation for 3 minutes at 95oC   
7. Denaturation at 98oC for 20 seconds 
8. Annealing at 62oC for 15 seconds 
9. Extension at 72oC for 1 minutes 
10. Final extension 72oC for 2 minutes 
Electrophoresis 
For the electrophoresis of all PCR products 1% agarose gels were used; for a 100ml 
gel, 1gr of agarose was added to 100ml of 1x TBE buffer and staining was done by using 1x 
SYBR® Safe DNA Stain (Catalogue no. S33102, Life Technologies) in the gel. 
 
Preparation of DNA constructs 
Following their amplification, the upstream and downstream regions of the genes of 
interest were inserted into a vector-plasmid. The vector used for the preparation of DNA 
constructs was plasmid pL0035 (Figure 8), which contains regions of multiple restriction 
sites, a resistance gene for ampicillin (amp), two 3’ UTRs of P. berghei’s dhfr gene 
(3’pbdhfr/ts), a human dhfr gene which makes the cells resistant to pyrimethamine (hdhfr), 
gene yfcu which produces an enzyme that catalyzes the transformation of prodrug 5-FC 
(5-Fluorocytosine) to a substance that is toxic to the cells and is used for negative selection 
(yfcu)42. The expression of the selection cassette is under the regulation of a constitutive 
promoter which is active all through the cell cycle of P. berghei (pbeef1aa). 
 
Figure 8: Plasmid pL0035. 
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Digestion of insert and vector 
The enzymes (acquired from New England Biolabs) used for the digestion of the 
upstream regions were HindIII (20u/μl) or ApaI (50u/μl) and SacII (20u/μl). ApaI was used 
for upstream regions in which the HindIII restriction site was present more than once. All 
downstream regions were cut with KpnI (20u/μl) and XhoI (20u/μl). 
For the digestion of the insert the following are added in a 1.5ml Eppendorf tube: 50μl of 
the PCR product, 6μl Buffer 4, 0.6μl BSA, 1μl Enzyme 1, 1μl Enzyme 2 and 1.4μl ddH2O. The 
tubes are incubated for two hours at 37oC*. 
For the digestion of the vector the following are added in a 1.5ml Eppendorf tube: 10μl of 
the vector, 6μl Buffer 4, 0.6μl BSA, 1μl Enzyme 1, 1μl Enzyme 2 and 41.4μl ddH2O. The tubes 
are incubated at 37oC for two hours*. After the vector islinearized, 1.0μl of CIP is added and 
the vector is incubated for 30 minutes at 37oC. Alkaline Phosphatase, Calf Intestinal (CIP) 
nonspecifically catalyzes the dephosphorylation of 5' and 3' ends of DNA and it prevents 
religation of linearized plasmid DNA. 
* ApaI is the only enzyme which functions at 25oC, so in the cases where it is used, ApaI is 
added in the beginning and the reaction mix is incubated at 25oC for two hours. 
Afterwards, SacII is added and the tubes are incubated at 37oC for two hours as usual. 
Ligation of the insert in vector 
All the ligation reactions were performed with 25ng of vector DNA and a vector to 
insert ratio of 1 to 3. For the ligation of any insert into a plasmid, 25ng of vector DNA were 
added to the needed amount of insert DNA (as calculated by ligation calculator43), 2μl of 
5x dilution buffer* and ddH2O up to 10μl. Afterwards, 10μl of 2x ligation buffer* and 1μl of 
DNA ligase* were added. The reaction mix was incubated at room temperature for 15 
minutes and used for transformation. 
*These reagents were obtained from the Roche rapid DNA ligation kit (Cat. No. 11 635 379 
001). 
Transformation of bacteria with plasmid DNA 
E. coli competent cells were used for chemical transformation. 2μl of the ligation mix 
were added to 100μl of E. coli cells and incubated on ice for 30 minutes. The cells were 
heat-shocked at 42oC for 45 seconds and transferred on ice for 1 minute. 500μl of LB broth 
were added and the cells were incubated for 1 hour at 37oC at approximately 200rpm. The 
cells were subsequently spun down at maximum rpm for 20 seconds, 500μl of the 
supernatant were removed and the pellet was resuspended in the remaining 100μl. The 
resuspended pellet was plated in LB agar plates containing ampicillin (100μg/ml) and 
incubated overnight at 37oC. 
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Diagnostic digestion 
The presence of the insert in the pL0035 vector was confirmed with diagnostic 
digestions of plasmid DNA extracted from the ampicillin resistant colonies. For that purpose 
the colonies were picked and incubated overnight in 3ml LB broth with ampicillin 
(100μg/ml) at 37oC and 200rpm. The plasmid DNA was then extracted from the cultures* 
and the diagnostic digestions were performed using the same enzymes that were used for 
the digestion of the insert and vector.  
Note: Once the insertion of the upstream region of a gene in the vector is confirmed, the 
same process is carried out for the downstream region of the gene (digestion, ligation, 
transformation and diagnostic digestion). For the downstream region the vector used is 
plasmid pL0035 with the upstream region of the gene which was constructed previously. 
*Plasmid DNA was extracted from the cultures with the use of Qiagen plasmid mini 
preparation kit. 
Final digestion 
When both the upstream and the downstream regions are present in the plasmid, 
the vector is completed. A large quantity of plasmid DNA* is obtained from 100ml cultures, 
done in LB broth with ampicillin, of E. coli cells transformed with the construct. The 
digestion was performed to remove the plasmid backbone from the required fragment of 
the vector containing the homologous arms and selectable marker.  
The final digestions were set up as follows: 80μgof vector, 1x buffer 4 (10x stock), 1x BSA 
(100x stock), 0.4U/μl ApaI or HindIII (depending on the vector), 0.4U/μl XhoI, 0.4U/μl BsaI 
and ddH2O.All reactions had a final volume of 400μl. 
*Plasmid DNA was extracted from the cultures with the use of Qiagen plasmid midi 
preparation kit (catalogue number 12145). 
DNA precipitation 
To precipitate DNA, 1/10 of the sample’s final volume 3M sodium acetate (NaAc) 
and 2x of the sample’s final volume 100% Ethanol are added. The samples are incubated 
at -20oC from 3 hours to overnight. Afterwards, the samples are centrifuged at maximum 
rpm for 30 minutes at 4oC. The supernatant is discarded and the pellet is washed with 
500μl of 70% Ethanol. The samples are centrifuged at maximum rpm for 10 minutes at 4oC, 
the supernatant is discarded and the pellet is air dried to avoid ethanol carry over before 
being resuspended in 50-100μl of ddH2O. 
Diagnostic PCR 
Diagnostic PCR is performed for the confirmation of 5’ and 3’ integration in the 
parasite’s genome. To confirm the 5’ integration, a specific primer binding to a sequence in 
the 3’UTR of the dhfr gene (GU0205), present only in the construct, is used paired with a 
primer which binds to a sequence located upstream of the 5’ homology arm, present only 
in the parasite’s genome. To confirm 3’ integration, a primer binding to the 3’UTR of the 
dhfr (GU0204), present only in the construct, is paired with a primer binding to a sequence 
downstream of the 3’ homology arm, present only in the parasite’s genome. Another pair 
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of primers is also used to amplify the open reading frame of the gene (present in wild type 
parasites).  
The reagents used for diagnostic PCRs are the same as mentioned previously for the 
regular PCR reaction with a final volume of 25μl. The template used for diagnostic PCRs is 
DNA extracted from parasites that have potentially integrated the 5’ and 3’ UTRs. 
 
 
 
 Primer sequence Number  
GDH2 5' integration  GTCTTATTTTATCAATCGATATATCATTATACGG GU3005 
GDH2 3' integration   CATATTTACCATTGTTTTTAACATCGCCACAAC GU3006 
GDH2 orf forward AAATATTGTGCAACATTGCCACTTCCACTA GU3007 
GDH2 orf reverse GATGATATTTTGTCACAACTCAATGTTAAGTG GU3008 
GDH1 5' integration  GTATGTGTGCATATATGCTTATTCACCA GU3009 
GDH1 3' integration  TTGGGAACATATTGTCTTTACAAGAGATG GU3010 
GDH1 orf reverse  CTATTGTTGATGGCATATTAGCACCTTCAC GU3011 
GDH1 orf forward  AAATGACGCAATGCCGAGATAGTACCG GU3012 
GDH3 5' integration  GTTCAATTACTTTCTTATTCTGTGAAAACAACC GU3013 
GDH3 3' integration  CAAGAACGAAACATGTATAAGAAGCGAAC GU3014 
GDH3 orf forward  ATGTCCATCCGTAACATTATCACCTGCA GU3015 
GDH3 orf reverse  CATTATTCCAGTCCCTAAATTACTAGATCCAG GU3016 
OAT 5' integration  CACAAGCAAAACGATACACATTCACTTGTT GU3017 
OAT 3' integration  GTAATAATAAATGTACTAATATCTTCACCGTC GU3018 
OAT orf forward  GGAGCTCACAATTATGATCCCATTCCC GU3019 
OAT orf reverse GTTTTGTCATGAACATCCCTAGTAATTAAACC GU3020 
put. transporter 5' integration  TCAATCGTTTCGTTAGCTAAATTGTCGTTTC GU3021 
put. transporter 3' integration  GCTTATACAAGACTTAAGTAGTTAGACAG GU3022 
putative transporter orf CTAAAATGGCAAAAACAACCCATCCATAATG GU3023 
putative transporter orf TCTTGAATTTTCAAGGAGGGATTGTTCG GU3024 
LDC 5' integration  ACAGTATGTTGCTAAAGAACACACGGAA GU3025 
LDC 3' integration  CTTTATTTAGGCCAATACTTGTCTTACTC GU3026 
LDC orf forward  ATCCGCCTGGATTTCCTGTATTAGTG GU3027 
LDC orf reverse  TGTTGGTAGAAGTATTCTGAACGCTTGC GU3028 
Table 5: Primers used for 3’ and 5’ UTR integration. 
 
34 
 
PCR for negative selection 
The reagents used for a PCR reaction to confirm the presence of negatively selected 
parasites are the same used for a normal PCR reaction except for the template and the 
primers. In this case DNA isolated from parasites that have possibly looped out the cassette 
following the 5-FC treatment is used as template.  
 
Table 6: Primers used for confirmation of negative selection. 
 Primer Sequence Number  
GDH1 upstream 
forward 
actAAGCTTCTATGTATATATTTTTCGACATTTAACTGC GU2943 
 
 
 
GDH1 
downstream 
reverse 
ctaCTCGAGCCGAGATGTTGTAGAGCATCATATGTATGAC GU2946 
hDHFR exon 
forward 
ATGGTTGGTTCGCTAAACTG GU0051 
Yfcu exon 
reverse 
TGATAGCACTACCACCGGTG GU0054 
 
 
2b.2 Plasmodium berghei methods 
Monitoring the parasitemia from Giemsa stained blood smears 
Blood smears are made from infected mice or from in vitro parasite cultures. 
Smears from infected mice are made with one drop of tail blood. For the preparation of 
smears from parasite cultures, 1ml of the culture is transferred to an Eppendorf tube, 
centrifuged at maximum rpm for 20 seconds and most of the supernatant is removed. The 
smear is made from the resuspension of the cells in the remaining 5-10μl of medium. 
Once the slides are prepared, the cells are fixed in methanol for 5 seconds and the slides are 
left to dry for 5 minutes. Afterwards, they are stained in 12% Giemsa solution and staining 
buffer for 15 minutes, rinsed in water and air dried.  
Calculation of parasitemia 
Parasitemia of infected mice is monitored by observation of Giemsa stained blood 
smears in the microscope.  
 
 
Treatment with phenylhydrazine-HCl 
P. berghei parasites prefer to invade reticulocytes rather than mature red blood 
cells. To induce the production of more reticulocytes, mice are injected with 0.1ml of phz-
Parasitemia = 
Number of iRBCs 
Number of total RBCs 
     x100 
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HCl stock solution (12.5mg/ml) made up in 0.9% NaCl usually 2 days prior to their infection 
with parasites. Phz causes haemolysis, resulting in anemia and subsequently, increased 
erythropoiesis and production of more reticulocytes. 
Schizont cultures 
For the production of schizonts, 200μl of blood from mice infected with P. berghei 
parasites 2-3 days earlier are added to 10ml of media + AlbuMAX. The samples are 
centrifuged for 8 minutes at 1800rpm at room temperature, the supernatant is discarded 
and the pellet is resuspended in 5ml of media. The resuspended pellet is transferred into 
150cm2 tissue culture (TC) flasks and topped up with 35 ml of media (0.5-1% cell 
concentration). The TC flasks are gassed with special gas mix and incubated at 37oC 
overnight. 
Isolation of schizonts from cultures 
Parasite cultures are centrifuged and the pellets are resuspended in 50ml falcon 
tubes with 35ml of standard medium. 10ml of 55% Nycodenz solution is layered at the 
bottom of the tubes and they are centrifuged at 1800rpm for 20 minutes at room 
temperature (density-gradient centrifugation) without brake. The middle layer of cells, 
containing the schizonts, is transferred to another tube and centrifuged at 1800rpm for 8 
minutes at room temperature. The supernatant is discarded and the pellet is resuspended 
with approximately 1ml of media. 
Transfection of schizonts using electroporation 
Typically, 10μg of the digested vector is used for transfection of schizonts using 
electroporation. The schizonts are then injected intravenously (i.v) to naïve mice. 
Selection of transfected parasites 
The mice are treated with pyrimethamine following the completion of one cell cycle 
after the transfection (one day). Any parasites that have not been transfected will not 
carry the selectable marker (hdhfr) which makes them resistant to pyrimethamine and will 
not survive. 
Presence of the construct in the parasites is confirmed by Diagnostic PCR. 
Genomic DNA isolation of malaria parasites 
Parasitemia of the positive mice needs to be over 1% for collection of heart blood. 
The blood is collected with a 2ml syringe containing 100μl Heparine in a falcon tube 
containing 10ml PBS. The collected blood/PBS is centrifuged at 1800rpm for 8minutes and 
the supernatant is discarded. The pellet is resuspended in 30μl of 1x lysis buffer and 
incubated on ice for 5 minutes. The falcon tubes are centrifuged at 1800 rpm for 8 minutes 
and the supernatant is discarded. The parasite pellet is resuspended in 700μl of TNE buffer 
and 20μlRNase (10mg/ml) and 100μl 10% v/v SDS are added. The samples are incubated at 
37oC for 10 minutes and then 20μl Proteinase K (10mg/ml) is added. The samples are 
incubated at 37oC for one hour. After the incubation, buffered phenol is added up to 1.5ml, 
the samples are mixed by inverting the tubes several times and centrifuged at maximum 
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rpm for 5 minutes. Subsequently, the upper phase is transferred to new Eppendorf tubes 
and buffered phenol: chloroform: isoamylalcohol (25: 24: 1) is added up to 1.5ml. The tubes 
are mixed, centrifuged at maximum rpm for 5 minutes and the upper phase is transferred 
to new Eppendorf tubes. Chloroform: isoamylalcohol (24: 1) is added up to 1.5ml, the tubes 
are mixed and centrifuged at maximum rpm for 5 minutes. The upper phase is transferred 
to new Eppendorf tubes and the parasite DNA is precipitated according to the protocol for 
precipitation of DNA. 
Cloning of transfected parasites 
The uncloned transfected parasites are injected i.pin mice treated with 
pyrimethamine. When the parasitemia is 0.1-1% a drop of blood is diluted in PBS and the 
solution is used to count the number of cells with the hemocytometer. Based on the 
parasitemia, counted in Giemsa stained smears, a solution of infected RBCs in PBS is made 
containing 0.8 infected RBCs in 200μl. 200μl of the solution is injected intravenously in each 
mouse with a total of 10 mice injected per cloning experiment. 7-10 days after the injections 
Giemsa stained smears are made from the mice to check the presence of parasites in their 
blood stream. If less than 8-9 mice are positive for parasites the cloning is successful. The 
positive mice are bled when parasitemia is 1% or over. DNA of the parasites is isolated and 
the presence of wild type and mutant parasites is checked by diagnostic PCRs. 
Negative selection 
A mouse is infected with parasites from the cloned line and if parasites are visible on 
Giemsa stained smears one day after the infection the mouse is treated with 5 
fluorocytocine (5fc) in drinking water. The parasitemia initially reduces after treatment 
with 5 FC, but after 5-6 days the number of parasites increases again. When parasitemia 
reaches 1% or over, the mouse is bled and DNA is isolated from the parasites. The DNA is 
used as template in a PCR reaction to determine if negative selection in the parasites was 
successful.  
Exflagellation of male gametocytes 
Activation of male gametocytes is induced with the addition of 100μl of blood from 
an infected mouse to 3ml of ookinete media (3%). The blood-ookinete media solution is 
incubated at room temperature (21-23oC) for 20 minutes. 10μl of the culture is used to 
count the exflagellation centers using the hemocytometer. 
Ookinete conversion of female gametocytes 
Conversion of female gametocytes to ookinetes occurs after incubation of 3ml 
cultures of ookinete media containing 100μl of blood from infected mice (3%) at 21oC for 21-
24 hours. Afterwards, smears from the cultures are made, stained with Giemsa and the 
conversion rate is calculated as follows. 
 
 
Number of ookinetes 
Ookinetes + female gametocytes 
Conversion rate = x100 
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Growth assay 
To examine the rate of growth of a mutant P. berghei line compared to wild type, 
equal number of parasites (~105) of line 733cl1 (wild type parasites expressing RFP in all 
stages) and line 1025cl2 (MRP1 mutant parasites expressing GFP in all stages) are injected 
into the same naïve mouse. The parasites’ growth is monitored over a period of 10 days by 
flow cytometry (FACS) analysis. When the parasitemia reaches 3-5% the parasites are 
passaged to naïve mice to continue the growth assay. 
A mouse injected with equal amount of parasites from line 733cl1 (RFP) and line 507 (wild 
type expressing GFP throughout the cell cycle) is used as a control. 
Mice used for FACS analysis are not treated with phenylhydrazine due to problems with 
auto-fluorescence (background) during flow cytometry analysis. 
Monitoring gametocyte production 
To monitor the production of gametocytes by different cloned lines, mice are 
infected by intraperitoneal injection with individual parasite lines. The lines used for this 
purpose are made in an 820 background resulting in the expression of GFP from male 
gametocytes and RFP from female gametocytes44. The gametocyte production is 
monitored with flow cytometry (FACS) over a period of 3-5 days following the protocol 
described below. During that period of time when the parasitemia is higher than 6% the 
parasites are passaged to naïve mice to avoid multiply infected red blood cells. 
Blood from an uninfected mouse is used as a control. 
Mice used for FACS analysis are not treated with phenylhydrazine due to problems with 
auto-fluorescence (background) during the flow cytometry analyses.  
Drug assay 
The effect of dihydroartemisine (DHA), atovaquone and primaquine on schizonts of 
lines 507tbb and 1025cl1 was tested to check for difference in drug sensitivity profiles of the 
MRP1 mutant and wild type parasites. Schizont cultures of the wild type and the mutant 
line were prepared and the schizonts were isolated using density-gradient centrifugation as 
described previously. The schizonts were injected intravenously into naïve non-phzed mice 
and 2-3 hours after the injections Giemsa stained smears were made to confirm the 
presence of ring stage parasites. The mice were bled and equal amounts of blood (1%) were 
put into culture plates containing standard media with a drug. The plates were gassed 
using gas mix and incubated at 37oC for 24 hours. 1ml from each culture was transferred to 
Eppendorf tubes, the cells were fixed with 0.25% glutaraldehyde/PBS solution and the 
samples were prepared for FACS analysis according to the protocol described below. 
Each culture plate contained one of the drugs mixed with the media in different 
concentrations and for each drug concentration there were two replicates. All the drugs 
were tested in the following concentrations: 100μM, 50μM, 10μM, 5μM, 1μM, 500nM, 100nM, 
50nM, 10nM, 5nM and 1nM. Cultures containing no drug were used as controls. 
GABA analogues test 
The effect of GABA analogues on the production of gametocytes in lines 820tbb, 
1512cl1 was tested following the same procedure as the drug assay, only in this test the 
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culture plates were incubated for 38 hours and the cells were not fixed for the purposes of 
FACS analysis.  
Four analogues were tested, Baclofen, CGP55845, Isonipecotid acid and Bicuculine. 
The analogues were tested in the following concentrations: 1mM, 100μM, 10μM, 1μM, 100nM, 
10nM and 0. There were two replicates for each concentration and non-producer line 
G401cl1 was used as control. 
 
 
2b.3 Flow cytometry 
Protocol for FACS analysis of parasites 
The parasites can be acquired either from an infected mouse or from schizont 
cultures. In the latter case, 1ml of the culture is transferred into an Eppendorf tube and 
centrifuged for 20 seconds at maximum speed. The supernatant is discarded and the cells 
get fixed by resuspension of the pellet in 500μl of 0.25%glutaraldehyde in ePBS and 
incubation at 4oC for 10 minutes (if the cells do not need to be fixed, the last step is not 
carried out). The tubes are centrifuged for 20 seconds at maximum rpm, the supernatant is 
discarded and the cells are resuspended in 500μl of Hoechst solution.The samples are 
covered with aluminum foil, because Hoechst is photosensitive, and incubated at 37oC for 
30-60 minutes. After the incubation the samples are centrifuged for 20 seconds at 
maximum speed, the supernatant is removed and the cells are resuspended in 1ml of FACS 
buffer. The cell suspension is passed through a nitex membrane into FACS tubes to avoid 
the presence of any red blood cell clusters in the samples that might blood the machine.  
If the parasites are obtained from an infected mouse, a drop of blood from the tail is 
collected in an Eppendorf tube containing0.25% glutaraldehyde in ePBS and the same 
procedure is carried out. 
 
 
2b.4 Metabolomics methods 
Phzed (reticulocytosis induced) mice were infected with P. berghei parasites from 
lines 820TBB, 1512cl1 and G401cl1. An uninfected mouse was used as control. The mice were 
bled 3 days after their infection and the blood was used for schizont cultures overnight*. 
Schizonts were isolated from the cultures using density gradient centrifugation. 
Subsequently, the purified schizonts were injected intravenously to naïve mice that had 
been phzed 5 days before (to allow for maximum number of reticulocytes to be present at 
the time of parasite incubation). This procedure was performed for synchronization of the 
parasites in the blood stream. After the completion of one cell cycle, 24 hours after the 
infection of the mice, the parasitemia was calculated from Giemsa stained smears and was 
18-20%. Blood was collected from the mice one hour later, filtered to remove white blood 
cells using Plasmodipur® filters and centrifuged at 1800rpm for 8 minutes at room 
temperature. The supernatant was discarded and the pellet was resuspended in minimal 
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media. The last two steps were repeated three times before the red blood cells were used 
for schizont cultures. Each culture contained 6x10e8 cells and was topped up with minimal 
media to 12ml. The cultures were incubated at 37oC. 
*In all the schizont cultures of this experiment minimal media was used to avoid any 
unnecessary background during the metabolomics analysis. 
Metabolite extraction and storage 
Metabolite extractions were performed at three time points; 6, 14 and 26 hours after 
the injections of purified schizonts into naïve mice.  
At each time point the flasks were submerged in dry ice and ethanol baths 
immediately after their removal from the incubator to quench the metabolism. A 
thermometer was inserted in the cultures to read the temperature and the flasks were 
removed from the dry ice-ethanol bath as soon as it reached 8oC, at this point the actual 
temperature of the cultures was around 0oC. The 12 ml cultures were split to 6 tubes, so 
that each tube contained 10e8 cells, and centrifuged at 5000rpm for 5 minutes at 4oC. 10μl 
of the supernatant were used for extractions in 150μl extraction solvent (supernatant 
suspensions) and the rest of the supernatant was removed. Subsequently, each pelletwas 
resuspended in 150μl extraction solvent (pellet suspensions). The suspensions, both pellet and 
supernatant, were mixed vigorously on shaker for 1 hour at 4oC and centrifuged at 
12000rpm for 5 minutes at 4oC. 100μl of the supernatant was transferred into glass vials, 
topped with Argon gas and stored at -80oC.  
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3a Lack of MRP1 leads to reduction in gametocytogenesis 
inPlasmodium berghei 
 
3a.1 Introduction 
MRP1 belongs to the ABCC sub-family of the ATP-binding cassette (ABC) 
superfamily, one of the largest evolutionary conserved families of proteins. Acquired 
resistance to several drugs has been linked to mutations in proteins-members of the ABCC 
sub-family. It has been demonstrated that polymorphisms resulting in changes in just a few 
amino acids in the sequence of these transporters are sufficient for acquisition of 
resistance45. Polymorphisms in P. falciparum chloroquine resistant transporter (pfcrt) were 
associated with resistance to the drug 46. Additionally, mutations in pfmdr encoding for the 
P-glycoprotein homologue 1 have been linked to resistance to several antimalarial drugs, 
such as mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. MRP1 was first 
identified in human tumour cells when it was discovered that the resistant cells did not 
overexpress any other protein known to induce resistance to anticancer substances, for 
example MDR1. It has been demonstrated that in humans, the protein can transport 
several compounds and organic anions, glutathione and sulphate conjugates, glucuronides 
as well as oxidized glutathione (GSSG)47. 
 Plasmodium berghei lines 1025cl1 and 1512cl1 were generated by knocking out the 
MRP1 gene for the purpose of determining its function (these lines were obtained from the 
Leiden University Malaria Research group). P. berghei mrp1 (PBANKA_144380) is located 
on chromosome 14 and consists of one exon (Figure 9a). The gene encodes a protein of 1935 
amino acids. PbMRP1 possesses the usual MRP structure (Figure 9b) comprising two 
transmembrane domains (TMDs) and two nucleotide binding domains (NBDs). Within the 
mrp1 sequence of P. berghei six characteristic motifs of the nucleotide binding domains of 
ABC proteins have been identified; Walker A and B, ABC motif, as well as Q-, D- and H- 
loop. 
 
Figure 9: P. berghei’s MRP1 
a. mrp1 (PBANKA_144380) 
annotated in the genome 
b. Structure of P. berghei’s MRP1 
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3a.2 Results 
The phenotypic characterization of the mutant as compared to the wild type was 
performed including asexual growth assay, gametocyte monitoring, exflagellation of male 
gametocytes and ookinete conversion in vitro. Characterization of the mutant lines 
revealed that lack of MRP1 had no effect on the asexual stages of the parasites but led to 
reduction in gametocytogenesis. 
The phenotypic analysis demonstrated that the mutant parasites were able to grow 
and multiply normally inside red blood cells of the vertebrate host (Figure 10). 
 
 
Asexual Growth assay: 
An asexual growth assay was performed by FACS analysis to determine whether the 
mutant parasites had an advantage or a defect over wild type parasites (the experiment 
was only performed once). For this experiment lines 1025cl1 (mrp1 ko) and 733cl1 (wild 
type) were used. The experiment needs to be repeated for a longer period of time, as in 
this data set, it was observed that by day 9 and 10 the mutant line seemed to start to 
outgrow the wild type line (Figure 11). 
 
Gametocyte production:  
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Figure 11: Growth assay for lines 1025cl1 and 733cl1.  
Parasites were passaged to naïve mice on the days indicated by arrows (day 2, 5 and 8).  
Day 1 was not included in the analysis due to very low parasitemia. 
 
 
Figure 10: Asexual stages of parasites from lines 820tbb and 1512cl1. Ring (a), 
trophozoite (b) and schizont (c) stage parasites of the wild type and the mutant. 
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Monitoring gametocyte production by FACS, revealed a significant reduction in the 
number of gametocytes produced from the mrp1 mutant compared to wild type 
production (Figure 12).  
 
 
 
Exflagellation and ookinete conversion: 
The gametocyte monitoring clearly revealed a decline in gametocytogenesis in the 
mutant line. To examine whether the gametocytes that are produced by the mutant line 
are functional, we estimated the exflagellation (Figure 13a) and the ookinete conversion 
(Figure 13b) in lines 1512cl1 (mrp1 mutant) and 820tbb (wild type). 
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Figure 12: Gametocyte monitoring of wild type parasites (820tbb) and mrp1 mutant 
parasites (1512cl1). 
Figure 13: Exflagellation of male gametocytes (a) and ookinete conversion of female 
gametocytes (b).  
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In vitro drug assay: 
MRP1 has an essential role in cell detoxification in many organisms since it can export 
several toxic compounds in a conjugated or unconjugated form. To test whether the lack of 
the mrp1 gene would alter the parasite’s sensitivity to antimalarials, a drug assay was 
performed. The mutant parasites’ growth was compared to the development of wild type 
parasites in the presence of three different antimalarial drugs with flow cytometry. The 
drugs tested were dihydroartemisinine (DHA), atovaquone and primaquine. Lines 507tbb 
(wild type) and 1025cl1 (mrp1 mutant) were used; these lines are made in 507 background 
causing the parasites to express GFP in all stages. 
 The IC50 values calculated from the drug assay revealed that the mrp1 knock out 
parasites are approximately 20 times more sensitive to DHA than wild type parasites and 3 
times more resistant to atovaquone and primaquine (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
1 
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1 
Figure 14: Growth curves and IC50 values. Parasites from lines 507tbb and 1025cl1 growing in the 
presence of a. dihydroartemisine (DHA), b. atovaquone and c. primaquine. 
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3a.3 Discussion 
Artemisinin and its derivatives are amongst the most effective antimalarials to 
date. These endoperoxide-containing compounds interfere with the development of 
asexual blood parasites in the host, but also target the sexual stages of the parasite 
contributing to reduction of transmission. It was demonstrated that artemisinin derivatives 
lacking the endoperoxide bridge are devoid of antimalarial activity, indicating that the 
endoperoxide bridge is the key factor of the drug’s pharmacological activity48. The mode of 
action of these drugs is not completely understood so far. One of the proposed mechanisms 
of action for artemisinin and its derivatives suggests that endoperoxide containing 
compounds are converted into free radicals in the presence of intraparasitic iron and 
subsequently alkylate Plasmodium proteins and other targets in the parasite49,48. This 
mode of action could provide an explanation of the mrp1 mutant’s increased sensitivity to 
DHA. Detoxification from free radicals requires interaction with glutathione since it is a 
reducing agent and acts as an electron donor to free radicals. Lack of the MRP1 transporter 
could contribute to faster accumulation of free radicals inside the parasite, therefore the 
amount of the drug required for a toxic effect decreases and the parasites become more 
sensitive.  
Mutant lines 1025cl1 and 1512cl1 are knock outs of the mrp1 gene in Plasmodium 
berghei. Phenotypic analysis of the mutant lines revealed no difference in the asexual 
stages; parasites were able to develop and multiply normally. Gametocyte monitoring of 
the mutants however, dictated that lack of the mrp1 gene is responsible for more than 80% 
reduction in the number of gametocytes produced compared to the wild type. Although 
fewer in number, the gametocytes produced by the mutant seem to be functioning 
normally as the percentages of exflagellation and ookinete conversion are within the 
normal range.  
The substrates of MRP1 in Plasmodium are yet to be determined, but none of the 
substrates identified in other species has been known to be essential for gametocyte 
production. Since lack of the protein interferes with the parasite’s ability to produce normal 
number of gametocytes and, to some extent, transmission of the disease, we attempted to 
identify the substrate(s) of MRP1 in P. berghei using metabolomics. 
  
 
 
 
 
 
 
 
 
45 
 
3b Metabolomics reveals differences in Plasmodium berghei lines 
with differential gametocyte conversion 
 
3b.1 Introduction 
Metabolomics involves study of all small molecule metabolites – products or 
intermediates of the metabolism of a single cell, a tissue or an entire organism. The 
metabolome is subjected to immediate changes as a result of ongoing biochemistry in the 
system studied. Any observed change in the metabolome, can be due to a number of 
conditions, such as treatment with a drug or an inhibitor or induced genetic alterations. 
Epigenetic regulation and post translational modifications can interfere with the study of 
the genome and the proteome, whereas the metabolome can provide a snapshot of the 
cells’ biochemical activity and contribute in correlating the observed phenotype with 
biochemical changes28.  
When a set of metabolites or a specific pathway is under examination targeted 
metabolomics approaches are used. Otherwise, untargeted approaches are taken, when 
the entire metabolome is examined. An untargeted metabolomics analysis aims to identify 
and measure as many metabolites as possible50.  
In this study, an untargeted metabolomics approach was used to point out the 
metabolic pathway(s) affected by the lack of the mrp1 gene in an attempt to identify the 
protein’s substrates and define specific function. For metabolomics analysis, the separation 
method used was High Performance Liquid Chromatography (HPLC) and the detection 
method was Mass Spectrometry (MS).  
High Performance Liquid Chromatography (HPLC) is a separation method in which 
the sample is introduced into the mobile phase and passed through a stationary phase 
column where the metabolites contained in the sample are separated based on their 
ability to be retained in the column which is determined by their inherent chemical 
properties. When a metabolite is separated from the sample its purified form can be eluted 
and the time required for a metabolite to elute off the column (retention time) is 
measured with HPLC. Following their separation, the mass of all the different metabolites 
is determined using Mass Spectrometry (MS). MS is an analytical technique in which the 
sample is introduced into the ionisation source, where it is ionized by electron 
bombardment. Based on the deflection of each ion, its mass is calculated by the detector; 
lighter ions are deflected more than heavier ions50.  After a sample is analysed with LC/MS, 
the metabolites are identified based on their retention time and calculated mass using 
standards and information from existing databases (Figure 15). 
 
Figure 15: Metabolomics data 
analysis method. Compounds 
are matched to metabolic 
pathways based on their mass and 
retention time. 
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3b.2 Results 
 For the metabolomics analysis, purified schizonts of lines 1512cl1, 820tbb and G401cl1 
were injected intravenously into naïve mice in order to synchronize the parasites in the 
bloodstream. The mice were bled when the parasites where at young ring stage and used 
for schizont cultures. Metabolite extractions from the schizont cultures were performed at 
three time points: 
 6 hours after the i.v injections at which point the parasites are at ring stage 
 14 hours post the i.v injections when the parasites are at trophozoite stage 
 26 hours after the i.v injections when the parasites are at schizont stage. 
The extracts were sent for HPLC/MS analysis to the Glasgow Polyomics facility. 
 
 More than 700 putative metabolites were detected in the pellet and supernatant 
extracts. Analysis of the data from HPLC/MS revealed that changes in the abundance of 
many of the identified metabolites were noted mostly in just one or two of the three time 
points and were not consistent. In a PCA plot analysis each sample is compared to all the 
other samples. When two samples appear close on the PCA plot it means that their 
metabolic profiles are similar. Ring stage parasites from the wild type, the low producer 
and the non-producer all cluster together in a PCA plot, revealing their metabolic 
resemblance. The results were similar for the trophozoite and schizont stages. Therefore, the 
stage specific metabolism appears to be largely conserved between the lines (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CV 
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Figure 16: PCA plot analysis of pellet samples. 
WT: wild type, GLP: gametocyte low producer, GNP: gametocyte non-producer.  
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In a volcano plot analysis two samples are compared with each other. A volcano 
plot analysis of the pellet suspensions revealed that only a few metabolites have a 
significant fold change between the wild type and the gametocyte low producer and 
thatthe changes were consistent in all time points only for three of these metabolites 
(Figure 17). The metabolites with consistent changes in all three time points are 3-
Methylguanine, Pro-Ser-Ser and 4-Aminobutanoate (GABA) (Figure 18).  
 
 
 
 
 
 
 
 
 
 
2 2 log 2 Fold Change log  Fold Change 
log 2 Fold Change 
Figure 17: Volcano plot analysis. Wild type vs gametocyte low producer at ring, throphozoite and 
schizont stage. 
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3b.3 Discussion 
 The first reports of using metabolomics to monitor metabolites present in urine using 
gas chromatography coupled with mass spectrometry were published in the 1970s. Since 
then, metabolomics analyses have been used in a variety of studies, ranging from single cell 
to mammalian organisms. Metabolomics has been applied to add information to genomic, 
proteomic and transcriptomic data and contribute towards making a complete picture of 
the biological system studied, but it can also provide novel information. Metabolomics 
approaches have been used to study protozoan parasites in different aspects providing 
valuable information concerning parasite-host interactions, putative drug targets, 
metabolic networks and possible drug action mechanisms51. 
 In this study, an untargeted metabolomics approach was used to study the 
metabolome of wild type, low producer and non-producer P. berghei parasites. LC/MS 
analysis of the samples resulted in the identification of more than 700 metabolites in the 
asexual stages. The PCA plot analysis revealed that stage specific metabolism appears to 
be largely conserved between the lines. In addition, comparison of wild type with low 
producer parasites in showed that the abundance of only a few metabolites differed 
significantly between the two lines. Loss of a gene is expected to have an impact on the 
metabolome of the parasites. Among the putative metabolites that where identified, only 
Figure 18: Metabolites with consistent 
change at 6, 14 and 26 hours. 
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three were found to be consistently changing across the studied time points; 3-
Methylguanine, 4-Aminobutanoate (GABA) and Pro-Ser-Ser. 
 Pro-Ser-Ser is a tripeptide which is most probably a product of haemoglobin 
degradation in the parasite and is 60% less in the MRP1 mutant compared to wt. 3-
Methylguanine is only present in the mutant parasites and is a metabolite that indicates 
DNA damage. Methylation of guanine could be a result of oxidative stress in the parasites 
lacking MRP1.  
 According to the phenotypic characterization of the mutant line the only difference 
between the wild type and the MRP1 mutant is the low production of gametocytes. Based 
on the literature and results of some experiments performed in P. falciparum 32 and P. 
berghei (personal communication A. Srivastava, unpublished data), we concluded that 
among the three metabolites GABA is the one that seems most likely to be involved in the 
sexual stage metabolism. We proceeded to investigate the role of GABA in the sexual 
stages of P. berghei.  
  
 
3c Elucidating the role of GABA as an energy reserve in sexual 
stages in P. berghei 
  
3c.1 Introduction  
The TCA cycle has been shown to be closely linked with GABA metabolism. The TCA 
cycle was thought to be absent from Plasmodium spp. since it was believed that the 
parasites rely primarily on glycolysis for ATP synthesis52 and that the enzyme pyruvate 
dehydrogenase is localised in the apicoplast30. Nevertheless, the presence of a single 
mitochondrion is essential for parasite survival and the genome encodes for all the genes 
necessary for the operation of the TCA cycle. Additionally, use of labelled glucose and 
glutamine in P. falciparum cultures resulted in the labelling of TCA cycle intermediates32. 
All the above provide evidence of a functioning TCA cycle in Plasmodium spp.  
The GABA shunt, as described previously, was recently shown to be functioning in T. 
gondii  36. However, as the Plasmodium genome does not encode for succinic semialdehyde 
dehydrogenase (SSADH), which is one of the enzymes necessary for the catabolism of 
GABA to succinate, or for glutamate decarboxylase, only a partial GABA shunt is possible 
in Plasmodium which does encode for the enzyme lysine decarboxylase PBANKA_100340 
(LDC), which is thought to have the same function as glutamate decarboxylase32.  
It has been demonstrated that perturbation of the TCA cycle can interfere with the 
development of sexual stages. Knock out of succinate dehydrogenase resulted in the 
production of non-functional ookinetes in P. berghei 33 and inhibition of aconitase using 
NaFAc, led to reduction of gametocytogenesis in P. falciparum32. Furthermore, high levels 
of labelled GABA were detected in gametocytes and even higher in ookinetes when heavy 
labelled isotope of glutamine was used in P. berghei cultures (personal communication, A. 
Srivastava, unpublished data). GABA seems to be accumulated in gametocytes and even 
more so in ookinetes, possibly to serve as an energy reserve in mosquito stages, where 
glucose is no longer abundant. Therefore, we decided to test whether the disruption of 
GABA metabolism could provide evidence for its role in ookinete development.  
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Genes that are possibly involved in GABA metabolism and were targeted for deletion 
are lysine decarboxylase (ldc-PBANKA_100340) and putative transporters of GABA and/or 
glutamate (gdh1-PBANKA_102620, gdh2-PBANKA_101400, gdh3-PBANKA_122820 and a 
put. transporter-PBANKA_030670). Ornithine amino transferase (oat-PBANKA_010740), 
which functions as a transporter and possibly converts a-ketoglutarate to glutamate, was 
also targeted (Figure 19). 
 
 
 
 
 
 
3c.2 Results 
To generate the knock out lines, the upstream and downstream regions of the genes 
were inserted into plasmid pL0035 and the correct ligation and insertion was confirmed 
with diagnostic digestions. Plasmid pL0035 containing the homology regions was used as 
vector for the transfection of P. berghei parasites and with double homologous 
recombination the genes were knocked outand mutants were selected by pyrimethamine 
treatment. At this stage the parasite population is mixed, consisting of wild type and 
mutant parasites. In order to isolate the mutant parasites the lines are cloned (for more 
details see sections 2b.1 and 2b.2 of Methods). 
 
 
Figure 19: GABA metabolism in Plasmodium. 
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 Glutamate dehydrogenase 1 (PBANKA_102620) 
GDH1 was successfully knocked out in P. berghei with double crossover homologous 
recombination (Figure 20a). Lines G1007 (GDH1 knock out in 507 background) and G1013 
(GDH1 knock out in 820 background) were generated and successfully cloned (Figure 
20b).  
 
 
 
 
 
 
 
 
 
The GDH1 knock out lines were negatively selected in order to have the ability to 
create a double or triple knock out using the same selection cassette. For that purpose, 
mice are treated with 5-fc (see methods). The enzyme encoded by gene yfcu converts 5-fc 
into a substance that is toxic for the parasites, causing the single recombination of the two 
3’pbdhfr/ts and removal of part of the cassette (Figure 21a). Afterwards, the same 
selectable marker can be used for another gene knock out. Negative selection was 
Figure 20: GDH1 knock out. a) Schematic representation of the double homologous recombination 
taking place in mutant parasites b) Uncloned (G1007, G1013) and cloned lines of GDH1 knock outs, in the 
cloned lines the open reading frame band is not present ( G1007cl8 is not a cloned line, since the ORF band 
at 1.1kb is present). Abbreviations: 5’ – 5’ integration, 3’ – 3’ integration, ORF – open reading frame. 
a 
b 
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successful for G1007cl1 and G1013cl1 but the lines were not cloned due to time restrictions 
(Figure 21b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
Figure 21: Negative selection. a) Single recombination of 3’pbdhfr/ts b) negatively selected 
G1007cl1 and G1013cl1, primers GU2943+GU2946 have a product of 5.5kb before negative selection 
and 2.6kb in negatively selected parasites (primers GU051+GU054 bind only if the cassette is present 
and were used as control). Abbreviations: 5’ – 5’ integration, 3’ – 3’ integration, ORF – open reading 
frame. 
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 Glutamate dehydrogenase 2 (PBANKA_101400) 
GDH2 was successfully knocked out in backgrounds 507 (line G1058) and 820 (line 
G1055). The lines need to be cloned for isolation of the mutant parasites (Figure 22). 
 
 
 
 
 
 
 
 
Figure 22: GDH2 knock out with double crossover homologous recombination; 
generation of lines G1055 and G1058. Abbreviations: 5’ – 5’ integration, 3’ – 3’ 
integration, ORF – open reading frame. 
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 Glutamate dehydrogenase 3 (PBANKA_122820) 
GDH3 was successfully knocked out with double homologous recombination and lines 
G1006 (GDH3 knock out in 507 background) and G1012 (GDH3 knock out in 820 
background) were cloned (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
Figure 23: GDH3 knock out. a) Schematic representation of the double crossover 
homologous recombination resulting in deletion of GDH3 b) Successful cloning of lines G1006 
and G1012. Abbreviations: 5’ – 5’ integration, 3’ – 3’ integration, ORF – open reading frame. 
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 Ornithine amino transferase (PBANKA_010740) 
Lines G1009 and G1015 were generated by deletion of OAT in the 507 and 820 
background with double homologous recombination. The lines were successfully cloned 
(Figure 24). 
 
 
 
 
 
 
 
 
 
a 
b 
Figure 24: OAT knock out. a) Double crossover homologous recombination resulting in deletion of 
OAT b) Successful cloning of lines G1009 and G1015. Abbreviations: 5’ – 5’ integration, 3’ – 3’ 
integration, ORF – open reading frame. 
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 Putative transporter (PBANKA_030670) 
The putative transporter of GABA and/or glutamate was knocked out in the 507 
(G1010) and the 820 (G1016) background. The generated lines have not been cloned yet 
(Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Putative transporter knock out with double crossover homologous recombination. 
Generation of uncloned lines G1010 and G1016. Abbreviations: 5’ – 5’ integration, 3’ – 3’ integration, 
ORF – open reading frame. 
 
 
 
2kb 
1.6kb 
1kb 
850 
 
57 
 
 Lysine decarboxylase (PBANKA_100340) 
Deletion of LDC was not possible even after six attempts with double crossover 
homologous recombination. Only 3’ integration was detected in transfected parasites 
(Figure 26). Failure to knock out LDC could be due to the gene’s size (~5.5kb), that area of 
the genome could be difficult to target (as we had difficulty in amplifying the upstream 
region) or it could mean that the gene is essential and cannot be knocked out in asexual 
stages.  
 
 
 
 
 
Figure 26: LDC knock out. Schematic representation of the double crossover homologous 
recombination that could lead to knock out of LDC. Deletion was not successful. Abbreviations: 
5’ – 5’ integration, 3’ – 3’ integration, ORF – open reading frame. 
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 Phenotypic analysis of cloned lines 
Following their generation, the cloned mutant lines were phenotypically characterized. 
The production of gametocytes was monitored and the exflagellation of male gametocytes 
and ookinete conversion were checked. 
 
1. Glutamate Dehydrogenase 1 knock out (G1013cl1) 
Gametocyte monitoring of line G1013cl1 (GDH1 knock out in the 820 background) 
revealed no significant difference from the number of gametocytes produced by the wild 
type (Figure 27a). However, there seems to be a decline in exflagellation (Figure 27b) and 
in the ookinete conversion (Figure 27c)of the GDH1 mutant parasites.  
 
 
 
 
 
 
 
a 
Figure 27: : Phenotypic analysis of the GDH1 knock out. a) gametocyte monitoring 
b) exflagellation percentage and c) ookinete conversion rates of the wild type and the GDH1 
knock out(these experiments were performed twice and need to be repeated). 
 
b 
c 
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2. Glutamate Dehydrogenase 3 knock out (G1012cl1) 
Phenotypic analysis of the GDH3 knock out line showed no significant difference in 
the production of gametocytes (Figure 28a), exflagellation of male gametocytes (Figure 
28b) and ookinete conversion (Figure 28c) between the wild type and the mutant. These 
experiments were only performed once and need repetition.  
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Phenotypic analysis of the GDH3 knock out. a) gametocyte monitoring b) exflagellation 
percentage and c) ookinete conversion rates of the wild type and the GDH3 knock out. 
 
 
a b 
c 
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3. Ornithine Amino Transferase knock out (G1015cl2) 
Gametocyte monitoring and calculation of exflagellation and ookinete conversion 
for the OAT knock out were only performed once and need to be repeated in order to get 
reliable results.It seems that gametocyte production (Figure 29a) and ookinete conversion 
rates(Figure 29c) of the OAT mutant line are within the normal range but the 
exflagellation of male gametocytes is reduced (Figure 29b). These experiments were only 
performed once and need repetition.  
 
   
 
 
 
 
 
Figure 29: Phenotypic analysis of the OAT knock out. a) gametocyte monitoring b) exflagellation 
percentage and c) ookinete conversion rates of the wild type and the OAT knock out. 
 
a b 
c 
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3c.3 Discussion  
According to recent findings sexual stage parasites utilize the TCA cycle for energy 
generation. Also, gametocytes and especially ookinetes seem to accumulate GABA possibly 
to use as an energy reserve in the mosquito stages. Six genes that are likely to participate 
in the metabolism of GABA were targeted for making knock outs in P. berghei parasites. 
Glutamate decarboxylases (GDH1, 2, 3) as well as a putative transporter are all possible 
transporters of GABA and/or glutamate. Ornithine amino transferase (OAT)is also a 
putative transporter of GABA/glutamate but it could also have the same function as 
GABA-T, which converts the TCA cycle intermediate a-ketoglutarate into glutamate; the 
precursor of GABA. Finally, lysine decarboxylase (LDC) which is thought to catalyse the 
conversion of glutamate to GABA and GABA to glutamate was also targeted. The RNA 
sequencing data (A. Religa, unpublished data) show that RNA from all the targeted genes 
was detected in the sexual stages of P. berghei, but only gdh1 is highly transcribed in the 
ookinete stage and ldc in gametocytes (Figure 30). It is expected that deletion of any of 
these genes can provide evidence for the role of GABA shunt for ookinete development. 
 
 
Deletion of five of the targeted genes was possible in asexual stages (gdh1, 2, 3, oat 
and putative transporter) in the 507 and 820 background. The GDH1, GDH3 and OAT 
knock out lines were successfully cloned in both backgrounds. These genes were targeted in 
order to disrupt the metabolism of GABA in P. berghei and show its role in parasite 
development. For this purpose, a phenotypic analysis of the cloned knock out lines was 
performed. The phenotypic characterization of the GDH1, GDH3 and OAT knock outs 
included gametocyte monitoring, exflagellation and ookinete conversion rates. The GDH3 
knock out line (G1012cl1) shows no significant difference from the wild type in gametocyte 
production, exflagellation and ookinete conversion. In the GDH1 and OAT knock outs even 
though gametocyte production is normal, there seems to be a reduction in the 
exflagellation of male gametocytes. Ookinete conversion is not affected in the OAT knock 
out (G1015cl2), it is however slightly reduced in the GDH1 knock out (G1013cl1). These 
experiments need to be repeated before any conclusions about the role of GABA 
metabolism in the sexual stages can be drawn.  
Figure 30: RNA sequencing data for gdh1, 2, 3, oat, putative transporter and ldc. 
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4   Final discussion  
 Transporter protein MRP1 has been identified in mammals and in a variety of non-
mammalian organisms, such as protozoa, yeast, nematodes and plants. This particular 
protein can transport a wide range of substrates, including several drugs as well as 
glutathione and glucuronate conjugates which are products of Phase II metabolism in cells. 
It is therefore involved in detoxification mechanisms and protection of the cell from endo 
and xenobiotics27. We demonstrated that P. berghei parasites lacking only the MRP1 gene 
produce 80-90% less gametocytes than wild type parasites. These gametocytes, although 
fewer in number, seem to have normal exflagellation and ookinete conversion rates. The 
substrate(s) of MRP1 in Plasmodium is unknown, so we conducted a comparative 
untargeted metabolomics study of the MRP1 mutant and wild type lines aiming to find out 
which pathway(s) is affected by the lack of the transporter. Over 700 putative metabolites 
were identified with LC/MS analysis of samples. The samples contained extracts from 
synchronized parasites in all three stages (rings, trophozoites and schizonts). Analysis of the 
metabolomics data of the wild type (820tbb), the low producer (1512cl1) and the non-
producer control (G401cl1) revealed that the metabolic profiles of these lines are largely 
conserved across the life cycle in asexual stages. When the wild type and the low producer 
were compared in a Volcano plot analysis it was clear that the metabolomes of the wild 
type and the low producer lines are highly similar in all three time points the extractions 
were performed. In fact, only three metabolites were altered in a consistent manner in all 
three time points; Pro-Ser-Ser, 3-Methylguanine and GABA.  
The tripeptide Pro-Ser-Ser is probably a product of hemoglobin degradation in the 
parasites and is approximately 60% less in the mrp1 mutant. 3-Methylguanine is an 
indicator of DNA damage; methylated nucleotides are the origin of mutations due to 
mispairing and they can be identified in a variety of organisms ranging from bacteria to 
humans. Cells possess specific enzymes, called DNA glycosylases, which identify and excise 
methylated nucleotides from the DNA53. The presence of free 3-Methylguanine exclusively 
in the mutant parasites could indicate that the DNA is getting damaged, possibly by the 
accumulation of reactive oxygen species due to the lack of MRP1. 
 GABA is an amino acid known for its function as a neurotransmitter in mammalian cells.  
The abundance of GABA was found to be approximately 70% less in the mutant parasites. 
The reason that we focused on this metabolite was its participation in the TCA cycle and 
previous work (published32 and unpublished) considering the relation between the sexual 
stages of the malaria parasites and the TCA cycle. Targeting genes that are possibly 
involved in GABA metabolism (gdh1-2-3, oat, putative transporter and ldc) was not 
entirely successful; we were able to delete gdh1, gdh2, gdh3, oat and the putative 
transporter but not ldc. Phenotypic analysis of the cloned knock out lines for gdh1, gdh3 
and oat revealed that disruption of GABA metabolism seems to affect exflagellation and 
mostly ookinete conversion rates (the experiments need to be repeated). Our results could 
be explained by the fact that GABA may serve as an energy reserve in the mosquito 
stages. Finally, the mutant parasites were tested against the antimalarials 
dihydroartemisinine (DHA), atovaquone and primaquine. There was no significant 
difference between the wild type and the mutantparasites against atovaquone and 
primaquine, but the mrp1 mutant was approximately 20 times more sensitive to DHA 
compared to wild type. Since the mode of action for artemisinin and its derivatives is not 
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entirely known, we cannot explain these results with certainty, but one of the modes of 
action for these drugs suggests that the endoperoxide containing drugs are converted to 
free radicals in the presence of intraparasitic iron and cause alkylation of proteins. As 
explained previously, free radicals could accumulate faster in parasites lacking MRP1 
making them more sensitive to DHA. 
 
5 Future work 
 
Future work for this project includes metabolomics analysis of gametocytes in order to 
compare the metabolomes of the MRP1 knock out line and the wild type. Additionally, this 
comparison might reveal the substrate of the MRP1 protein, which is also one of the future 
objectives of this project. Furthermore, we need to tag MRP1 and the genes involved in 
GABA metabolism, using a fluorescent tag, for localisation. Concerning the genes we 
targeted for deletion, we need to create a triple knock out of gdh1, gdh2 and gdh3 in case 
there is functional redundancy. Phenotypic analysis of the triple knock out could help to 
determine the function of glutamate dehydrogenase in Plasmodium berghei.  Future plans 
also include knock out or disruption of the ldc gene or conditional degradation of its protein 
in gametocytes and ookinetes to study its function in mosquito stages in case it is indeed 
essential in asexual stages. The reason that deletion of the ldc gene was not possible using a 
regular vector could be that it is a big gene (almost 10kb), so the vector used for the knock 
out needs to have long arms. This knock out might be successful with the use of PlasmoGen 
recombineering vectors. Also, disrupting ldc by removing part of the gene could give some 
indication of its function. Moreover, we need to do phenotypic analysis of all the generated 
mutant lines; including oocyst and sporozoite development as well as transmission to naïve 
mice. Finally, we aim to do targeted metabolomics using heavy labeled isotopes of glucose 
and glutamine of the GABA metabolism mutants in order to examine the effect of 
disrupting GABA metabolism on major metabolic pathways. 
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